cd117-saporin

cd117-saporin is an experimental antibody-drug conjugate that couples an anti-CD117 (c-Kit) monoclonal antibody to the ribosome-inactivating toxin saporin, typically via a streptavidin–biotin linkage, to selectively ablate hematopoietic stem and progenitor cells without genotoxic chemotherapy or irradiation.[2][7][11] By binding CD117 on hematopoietic stem cells, internalizing, and releasing saporin intracellularly, the conjugate halts protein synthesis and induces cell death, enabling efficient donor hematopoietic cell engraftment and durable hematopoietic chimerism in mouse models while largely preserving downstream immune effector cells and overall immunity.[2][7] This non-myeloablative conditioning approach has been developed primarily in academic settings (e.g., Stanford/Harvard collaborations) as a platform strategy to improve the safety of hematopoietic stem cell transplantation and potentially support gene therapy and tolerance protocols for a range of malignant and non-malignant hematologic and immune diseases.[2][6][7]

Other names

CD117-ADC to saporinCD-117-ADC to saporinCD 117-ADC to saporinanti-CD117 saporin conjugateanti-CD-117 saporin conjugateanti-CD 117 saporin conjugateCD117 antibody-drug conjugate to saporinCD-117 antibody-drug conjugate to saporinCD 117 antibody-drug conjugate to saporinanti-c-Kit saporin conjugate